Welcome!
To use the personalized features of this site, please log in or register.
If you have forgotten your username or password, we can help.
My Menu
Saved Items

Symposium: Selected Papers Presented at the 2008 Meeting of the Musculoskeletal Tumor Society

Early Equivalence of Uncemented Press-fit and Compress® Femoral Fixation

German L. Farfalli1, Patrick J. Boland1, Carol D. Morris1, Edward A. Athanasian1 and John H. HealeyContact Information

(1)  Orthopaedic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center (Affiliated with Weill Medical College of Cornell University), 1275 York Avenue, Suite A342, New York, NY 10021, USA

Received: 2 December 2008  Accepted: 19 May 2009  Published online: 10 June 2009

Abstract  Bone ingrowth promises more durable biologic fixation of megaprostheses. The relative performance of different types of fixation is unknown. We compared the fixation of two forms of biologically fixed femoral components: an intramedullary uncemented press-fit stem (UCS; Group 1, 50 patients) and a Compress® uncemented fixation (CPS; Group 2, 41 patients). In Group 1, the overall Kaplan-Meier prosthetic survival rates were 85% at 5 and 71% at 10 years. Most failures were long-term developments. Aseptic loosening was the primary cause of failure. Stem diameters less than 13.5 mm and a diaphyseal/stem coefficient greater than 2.5 mm were associated with decreased prosthetic survival. In Group 2, the overall rate of CPS survival was 88% at 5 years. Failure of femoral fixation or fracture during the first year was the main reason for revision. Five-year survival rates were similar between the groups and we observed no difference in the functional success of the implants. We found no failures after 1-year followup in Group 2 (CPS). Any difference in prosthetic survival can only be proven by longer-term study or a randomized trial.
Level of Evidence: Level III, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.
Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article.
Each author certifies that his institution has approved the reporting of this study and that all investigations were conducted in conformity with ethical principles of research.

Contact Information John H. Healey
Email: healeyj@mskcc.org

References

1. Avedian R, Goldsby RE, Kramer MJ, O’Donnell RJ. Effect of chemotherapy on initial compressive osseointegration of oncologic endoprostheses. Clin Orthop Relat Res. 2007;459:48–53.
PubMed CrossRef ChemPort
 
2. Bhangu AA, Kramer MJ, Grimer RJ, O’Donnell RJ. Early distal femoral endoprosthetic survival: cemented stems versus the Compress® implant. Int Orthop. 2006;30:465–472.
PubMed SpringerLink ChemPort
 
3. Bickels J, Wittig JC, Kollender Y, Henshaw RM, Kellar-Graney KL, Meller I, Malawer M. Distal femoral resection with endoprosthetic reconstruction: a long-term followup study. Clin Orthop Relat Res. 2002;400:225–235.
PubMed CrossRef
 
4. Bini SA, Johnston JO, Martin DL. Compliant prestress fixation in tumor prostheses: interface retrieval data. Orthopedics. 2000;23:707–712.
PubMed ChemPort
 
5. Capanna R, Morris HG, Campanacci D, Del Ben M, Campanacci M. Modular uncemented prosthetic reconstruction after resection of tumours of the distal femur. J Bone Joint Surg Br. 1994;76:178–186.
PubMed ChemPort
 
6. Cristofolini L, Bini SA, Toni A. In vitro testing of a novel limb salvage prosthesis for the distal femur. Clin Biomech. 1998;13:608–615.
CrossRef
 
7. Enneking WF, Dunham W, Gebhardt MC, Malawer M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993;286:241–246.
PubMed
 
8. Finn HA, Simon MA. Limb-salvage surgery in the treatment of osteosarcoma in skeletally immature individuals. Clin Orthop Relat Res. 1991;262:108–118.
PubMed
 
9. Flint MN, Griffin AM, Bell RS, Ferguson PC, Wunder JS. Aseptic loosening is uncommon with uncemented proximal tibia tumor prostheses. Clin Orthop Relat Res. 2006;450:52–59.
PubMed CrossRef
 
10. Freedman EL, Eckardt JJ. A modular endoprosthetic system for tumor and non-tumor reconstruction: preliminary experience. Orthopedics. 1997;20:27–36.
PubMed ChemPort
 
11. Griffin AM, Parsons JA, Davis AM, Bell RS, Wunder JS. Uncemented tumor endoprostheses at the knee: root causes of failure. Clin Orthop Relat Res. 2005;438:71–79.
PubMed CrossRef
 
12. Healey JH, Abdeen A, Morris CD, Athanasian EA, Boland PJ. Telescope allograft method to reconstitute the diaphysis in limb salvage surgery. Clin Orthop Relat Res. 2008 Oct 3 [Epub ahead of print].
 
13. Horowitz SM, Glasser DB, Lane JM, Healey JH. Prosthetic and extremity survivorship after limb salvage for sarcoma: how long do the reconstructions last? Clin Orthop Relat Res. 1993;293:280–286.
PubMed
 
14. Jeys LM, Kulkarni A, Grimer RJ, Carter SR, Tillman RM, Abudu A. Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. J Bone Joint Surg Am. 2008;90:1265–1271.
PubMed CrossRef ChemPort
 
15. Kawai A, Healey JH, Boland PJ, Athanasian EA, Jeon DG. A rotating-hinge knee replacement for malignant tumors of the femur and tibia. J Arthroplasty. 1999;14:187–196.
PubMed CrossRef ChemPort
 
16. Kawai A, Lin PP, Boland PJ, Athanasian EA, Healey JH. Relationship between magnitude of resection, complication, and prosthetic survival after prosthetic knee reconstructions for distal femoral tumors. J Surg Oncol. 1999;70:109–115.
PubMed CrossRef ChemPort
 
17. Kawai A, Muschler GF, Lane JM, Otis JC, Healey JH. Prosthetic knee replacement after resection of a malignant tumor of the distal part of the femur. Medium to long-term results. J Bone Joint Surg Am. 1998;80:636–647.
PubMed CrossRef ChemPort
 
18. Kneisl JS, Finn HA, Simon MA. Mobile knee reconstructions after resection of malignant tumors of the distal femur. Orthop Clin N Am. 1991;22:105–119.
ChemPort
 
19. Kramer MJ, Tanner BJ, Horvai AE, O’Donnell RJ. Compressive osseointegration promotes viable bone at the endoprosthetic interface: retrieval study of Compress(R) implants. Int Orthop. 2008;32:567–571.
PubMed SpringerLink ChemPort
 
20. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, Wexler L, Demetri GD, Healey JH, Huvos AG, Goorin AM, Bagatell R, Ruiz-Casado A, Guzman C, Jimeno J, Harmon D. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer. 2003;98:832–840.
PubMed CrossRef ChemPort
 
21. Marshall AD, Mokris JG, Reitman RD, Dandar A, Mauerhan DR. Cementless titanium tapered-wedge femoral stem: 10- to 15-year follow-up. J Arthroplasty. 2004;19:546–552.
PubMed CrossRef
 
22. Meding JB, Keating EM, Ritter MA, Faris PM, Berend ME. Minimum ten-year follow-up of a straight-stemmed, plasma-sprayed, titanium-alloy, uncemented femoral component in primary total hip arthroplasty. J Bone Joint Surg Am. 2004;86:92–97.
PubMed
 
23. Meyers PA, Gorlick R, Heller G, Casper E, Lane J, Huvos AG, Healey JH. Intensification of preoperative chemotherapy for osteogenic sarcoma: results of the Memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1998;16:2452–2458.
PubMed ChemPort
 
24. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5–15.
PubMed ChemPort
 
25. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–2011.
PubMed CrossRef ChemPort
 
26. Mittermayer F, Krepler P, Dominkus M, Schwameis E, Sluga M, Heinzl H, Kotz R. Long-term followup of uncemented tumor endoprostheses for the lower extremity. Clin Orthop Relat Res. 2001;388:167–177.
PubMed CrossRef
 
27. Mittermeyer F, Windhager R, Dominkus M, Krepler P, Schwamels E, Sluga M, Kotz R, Strasser G. Revision of the Kotz type of tumor endoprosthesis for the lower limb. J Bone Joint Surg Br. 2002;84:401–406.
CrossRef
 
28. Muscolo DL, Ayerza MA, Aponte-Tinao LA, Ranalletta M. Use of distal femoral osteoarticular allografts in limb salvage surgery. J Bone Joint Surg Am. 2005;87:2449–2455.
PubMed CrossRef
 
29. Sanjay BKS, Moreau P. Limb salvage surgery in bone tumour with modular endoprosthesis. Int Orthop. 1999;23:41–46.
PubMed SpringerLink ChemPort
 
30. Shih LY, Sim FH, Pritchard DJ, Rock MG, Chao EY. Segmental total knee arthroplasty after distal femoral resection for tumor. Clin Orthop Relat Res. 1993;292:269–281.
PubMed
 
31. Torbert JT, Fox EJ, Hosalkar HS, Ogilvie CM, Lackman RD. Endoprosthetic reconstructions: results of long-term followup of 139 patients. Clin Orthop Relat Res. 2005;438:51–59.
PubMed CrossRef
 
32. Unwin PS, Cannon SR, Grimer RJ, Kemp HBS, Sneath RS, Walker PS. Aseptic loosening in cemented custom-made prosthetic replacements for bone tumours of the lower limb. J Bone Joint Surg Br. 1996;78:5–13.
PubMed ChemPort
 
33. Wunder JS, Leitch K, Griffin AM, Davis AM, Bell RS. Comparison of two methods of reconstruction for primary malignant tumors at the knee: a sequential cohort study. J Surg Oncol. 2001;77:89–99.
PubMed CrossRef ChemPort
 
34. Zwart HJ, Taminiau AH, Schimmel JW, van Horn JR. Kotz modular femur and tibia replacement. 28 tumor cases followed for 3 (1–8) years. Acta Orthop Scand. 1994;65:315–318.
PubMed ChemPort
 


Export this article
Export this article as RIS | Text
 
Remote Address: 38.107.191.103 • Server: mpweb05
HTTP User Agent: CCBot/1.0 (+http://www.commoncrawl.org/bot.html)